News | January 06, 2026
Wegovy pill marks first GLP-1 weight-loss medicine in oral form
The approval introduces a needle-free alternative to injectable GLP-1 therapies
The approval introduces a needle-free alternative to injectable GLP-1 therapies
The company is pursuing the accelerated FDA 505(b)(2) approval pathway for its once-daily oral ondansetron formulation
The SNS records neural activity from 60 channels across four brain regions—far exceeding current commercial devices
CystoSmart, an AI tool designed to detect bladder tumors during screening and surveillance cystoscopy, is brand-agnostic and works with flexible, rigid, and single-use scopes
Under the agreement, Insilico could receive up to $32 million in upfront and near-term R&D payments
Pembrolizumab has shown meaningful benefit only when combined with chemotherapy
The decision positions Yartemlea as the first and only approved inhibitor of the lectin pathway of complement
The FDA acknowledged that Corcept’s pivotal GRACE trial met its primary endpoint and that data from the GRADIENT trial offered confirmatory evidence
The Phase II study will assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of 9MW3811 in patients with pathological scarring
The filing clears the regulatory path for potential first-in-human trials and marks a key advance in the company’s chronic inflammatory disease pipeline
Subscribe To Our Newsletter & Stay Updated
